Internal Medicine, Gastroenterology · Wichita, KS
NPI
1225038029
Since 2005
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3121 N Webb Rd, Suite 101
Wichita, KS, 67226
Phone (316) 261-3130
Groups this clinician bills Medicare through
Medicare paid, 2024
$399K
14,469 services
Medicare patients, 2024
841
Average age 73
Drug cost, 2024
$5.4M
3,205 prescriptions
Company payments, 2025
$593
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael W Lievens was code J3380 (injection, vedolizumab, intravenous, 1 mg), 7,800 times for 17 patients. In total Michael W Lievens billed 14,469 services in 70 codes, and Medicare paid $399K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-08-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3380 Injection, vedolizumab, intravenous, 1 mg | Office | 7,800 | 17 | $17.42 | $136K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 1,720 | 16 | $24.95 | $43K |
| 88305 Surgical Pathology Examination | Office | 666 | 285 | $25.23 | $17K |
| 43239 Upper GI Endoscopy | Facility | 235 | 226 | $56.58 | $13K |
| 45385 Colonoscopy - Lesion Removal | Facility | 184 | 184 | $197.30 | $36K |
| 45380 Lower GI Endoscopy - Other | Facility | 161 | 161 | $82.77 | $13K |
| 99213 Office E&M - Established | Office | 156 | 128 | $65.60 | $10K |
| 43248 Upper GI Endoscopy | Facility | 121 | 106 | $110.61 | $13K |
| 99214 Office E&M - Established | Office | 114 | 90 | $95.55 | $11K |
| 99203 Office E&M - New | Office | 108 | 108 | $75.18 | $8,119 |
| 99204 Office E&M - New | Office | 82 | 82 | $117.55 | $9,640 |
| 96365 Intravenous Infusion, Hydration | Office | 53 | 20 | $48.15 | $2,552 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 42 | 42 | $177.15 | $7,440 |
| 43235 Upper GI Endoscopy | Facility | 37 | 37 | $76.97 | $2,848 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 32 | 32 | $179.33 | $5,738 |
By year: 2022 $539K for 27,078 services; 2023 $497K for 23,688 services; 2024 $399K for 14,469 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 666 | 285 | $25.23 | $17K |
Medicare prescription drug claims, 2024
In 2024, the drug Michael W Lievens prescribed most often to Medicare patients was Pantoprazole Sodium, with 562 prescriptions and refills. In total Michael W Lievens wrote 3,205 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 562 | 937 | 126 | $6,375 |
| Omeprazole Generic | 547 | 937 | 116 | $3,232 |
| Stelara Ustekinumab | 169 | 223 | 21 | $4.7M |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 131 | 137 | 39 | $3,780 |
| Ursodiol Generic | 113 | 162 | 21 | $11K |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 102 | 102 | 99 | $1,322 |
| Famotidine Generic | 92 | 168 | 21 | $789 |
| Baclofen Generic | 89 | 96 | 25 | $588 |
| Mesalamine Generic | 79 | 113 | 20 | $26K |
| Budesonide Dr Budesonide | 79 | 88 | 25 | $6,096 |
| Misoprostol Generic | 55 | 75 | 16 | $3,540 |
| Esomeprazole Magnesium Generic | 54 | 76 | Under 11 | $1,455 |
| Mesalamine Er Mesalamine | 50 | 56 | Under 11 | $6,772 |
| Ondansetron Hcl Generic | 48 | 48 | Under 11 | $337 |
| Prednisone Generic | 47 | 49 | 13 | $221 |
Brand drugs: 480 claims; generic drugs: 2,691 claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael W Lievens $593 ($593 in general payments such as food, travel and fees) from 8 companies. The largest payer was Abbvie Inc. with $313.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.